Rituximab is an immunosuppressive monoclonal antibody therapy that is used in some cases to help prevent relapses of neuromyelitis optica, an inflammatory CNS demyelinating disease. A new study provides evidence supporting efficacy and a strategy for optimizing the timing of repeated courses of treatment for the individual patient.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J. & Weinshenker, B. G. The spectrum of neuromyelitis optica. Lancet Neurol. 6, 805–815 (2007).
Lennon, V. A. et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364, 2106–2112 (2004).
Hinson, S. R. et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 69, 2221–2231 (2007).
Cree, B. A. et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64, 1270–1272 (2005).
Jacob, A. et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch. Neurol. 65, 1443–1448 (2008).
Pellkofer, H. L. et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76, 1310–1315 (2011).
Kim, S. H., Kim, W., Li, X. F., Jung, I. J. & Kim, H. J. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch. Neurol. http://dx.doi.org/10.1001/archneurol.2011.154.
Palace, J. et al. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch. Neurol. 67, 1016–1017 (2010).
Shimizu, J. et al. IFNβ-1b may severely exacerbate Japanese optic–spinal MS in neuromyelitis optica spectrum. Neurology 75, 1423–1427 (2010).
Hinson, S. R. et al. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Arch. Neurol. 66, 1164–1167 (2009).
Acknowledgements
The authors receive research support from the Guthy–Jackson Charitable Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D. M. Wingerchuk has received research support from Alexion, Genentech and Genzyme. B. G. Weinshenker serves as a member of data safety monitoring committees for clinical trials sponsored by Biogen-Idec and Novartis. He receives royalties related to a patent for a test for neuromyelitis optica that has been licensed to a third party, RSR.
Rights and permissions
About this article
Cite this article
Wingerchuk, D., Weinshenker, B. Optimizing rituximab therapy for neuromyelitis optica. Nat Rev Neurol 7, 664–665 (2011). https://doi.org/10.1038/nrneurol.2011.154
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2011.154
This article is cited by
-
Rituximab ist effektiv in der Langzeitbehandlung
InFo Neurologie & Psychiatrie (2012)